Immunotherapy

Triple-negative breast cancer accounts for 10 percent of breast cancer cases in the U.S. annually. As T-cells that normally kill cancer cells often become exhausted and stop, Vanderbilt pharmacologists are seeking chemotherapy or targeted therapy approaches that can enhance the T-cell killing of cancer cells. Read More

L-R: Ann Richmond, Chi Yan By Wendy Bindeman Ann Richmond, professor of pharmacology, and Chi Yan, a research assistant professor in the Richmond lab, recently published a study showing that expression of a protein called CD40 can be used to predict response to immunotherapy in malignant melanoma. Read More